Evaluation of clinical outcomes in systemic juvenile idiopathic arthritis patients treated with biological agents in Turkey : the TURSIS study
OBJECTIVES: Biological drugs are one of the most effective treatment methods for systemic juvenile idiopathic arthritis (SJIA) and can significantly prevent morbidity and mortality. This study aimed to evaluate the efficacy and safety of biologics in patients with SJIA and provide real-life data that might help improve the outcomes.
METHODS: TURSIS was a retrospective multicentre study carried out in patients with SJIA for whom a biological treatment had been initiated between 1st March 2013 and 30th December 2018. Data include patients' characteristics, laboratory-clinical results, outcomes, and safety-related variables. The 24-month follow-up data of the patients and the efficacy and safety of biological drugs were evaluated.
RESULTS: 147 patients were enrolled. The clinical course of the disease was as follows; it was monocyclic in 38.1%, polycyclic in 49%, and persistent in 12.9% of patients. First-choice biologics were interleukin (IL)-1 blockers in the majority of patients (56.5%), followed by the anti-IL-6 (25.2%) and anti-TNF-alpha drugs (18.4%). Anakinra was the most preferred biologic agent in patients with macrophage activation syndrome (MAS), and tocilizumab was used more frequently in patients with persistent type (p=0.000 and p=0.003). The most frequent switch rate was seen in patients receiving anakinra (n=40/68, 58.8%), and it was most frequently switched to canakinumab (n=32/40, 80%). Better physician's global assessment scores were achieved in patients treated with anakinra in Month 3, compared to other treatments (p=0.04).
CONCLUSIONS: The results of our study support the efficacy of biological drugs in particular anti-IL-1 and anti-IL-6 drugs, in the treatment of SJIA. These treatments resulted in improvement in activity of disease and provide a considerable decrease in the frequency of MAS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Clinical and experimental rheumatology - 42(2024), 1 vom: 01. Jan., Seite 194-201 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sozeri, Betül [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 05.02.2024 Date Revised 05.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.55563/clinexprheumatol/j611kr |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359977081 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359977081 | ||
| 003 | DE-627 | ||
| 005 | 20240205231843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.55563/clinexprheumatol/j611kr |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1281.xml |
| 035 | |a (DE-627)NLM359977081 | ||
| 035 | |a (NLM)37497697 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sozeri, Betül |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of clinical outcomes in systemic juvenile idiopathic arthritis patients treated with biological agents in Turkey |b the TURSIS study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2024 | ||
| 500 | |a Date Revised 05.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Biological drugs are one of the most effective treatment methods for systemic juvenile idiopathic arthritis (SJIA) and can significantly prevent morbidity and mortality. This study aimed to evaluate the efficacy and safety of biologics in patients with SJIA and provide real-life data that might help improve the outcomes | ||
| 520 | |a METHODS: TURSIS was a retrospective multicentre study carried out in patients with SJIA for whom a biological treatment had been initiated between 1st March 2013 and 30th December 2018. Data include patients' characteristics, laboratory-clinical results, outcomes, and safety-related variables. The 24-month follow-up data of the patients and the efficacy and safety of biological drugs were evaluated | ||
| 520 | |a RESULTS: 147 patients were enrolled. The clinical course of the disease was as follows; it was monocyclic in 38.1%, polycyclic in 49%, and persistent in 12.9% of patients. First-choice biologics were interleukin (IL)-1 blockers in the majority of patients (56.5%), followed by the anti-IL-6 (25.2%) and anti-TNF-alpha drugs (18.4%). Anakinra was the most preferred biologic agent in patients with macrophage activation syndrome (MAS), and tocilizumab was used more frequently in patients with persistent type (p=0.000 and p=0.003). The most frequent switch rate was seen in patients receiving anakinra (n=40/68, 58.8%), and it was most frequently switched to canakinumab (n=32/40, 80%). Better physician's global assessment scores were achieved in patients treated with anakinra in Month 3, compared to other treatments (p=0.04) | ||
| 520 | |a CONCLUSIONS: The results of our study support the efficacy of biological drugs in particular anti-IL-1 and anti-IL-6 drugs, in the treatment of SJIA. These treatments resulted in improvement in activity of disease and provide a considerable decrease in the frequency of MAS | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Interleukin 1 Receptor Antagonist Protein |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a Interleukin-1 |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Demir, Ferhat |e verfasserin |4 aut | |
| 700 | 1 | |a Barut, Kenan |e verfasserin |4 aut | |
| 700 | 1 | |a Atalay, Erdal |e verfasserin |4 aut | |
| 700 | 1 | |a Pac Kisaarslan, Ayşenur |e verfasserin |4 aut | |
| 700 | 1 | |a Özdel, Semanur |e verfasserin |4 aut | |
| 700 | 1 | |a Altuğ Gücenmez, Özge |e verfasserin |4 aut | |
| 700 | 1 | |a Makay, Balahan |e verfasserin |4 aut | |
| 700 | 1 | |a Aktay Ayaz, Nuray |e verfasserin |4 aut | |
| 700 | 1 | |a Haşlak, Fatih |e verfasserin |4 aut | |
| 700 | 1 | |a Sağ, Erdal |e verfasserin |4 aut | |
| 700 | 1 | |a Yıldız, Mehmet |e verfasserin |4 aut | |
| 700 | 1 | |a Kaya Akça, Ümmüşen |e verfasserin |4 aut | |
| 700 | 1 | |a Adroviç, Amra |e verfasserin |4 aut | |
| 700 | 1 | |a Bilginer, Yelda |e verfasserin |4 aut | |
| 700 | 1 | |a Poyrazoğlu, Hakan |e verfasserin |4 aut | |
| 700 | 1 | |a Ünsal, Erbil |e verfasserin |4 aut | |
| 700 | 1 | |a Kasapçopur, Özgür |e verfasserin |4 aut | |
| 700 | 1 | |a Özen, Seza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental rheumatology |d 1989 |g 42(2024), 1 vom: 01. Jan., Seite 194-201 |w (DE-627)NLM012613010 |x 0392-856X |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:194-201 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.55563/clinexprheumatol/j611kr |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 1 |b 01 |c 01 |h 194-201 | ||